Shares of Novavax Inc. NVAX slipped 3.24% to $7.17 Tuesday, on what proved to be an all-around mixed trading session for the ...

B. Riley decreased their FY2024 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley ...

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, ...

Stocks of makers of COVID vaccines, Moderna MRNA, Pfizer PFE, Novavax NVAX and BioNTech BNTX rose on Friday on reports of a new bat coronavirus being discovered in China. What is the New Coronavirus?

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax Inc. closed 68.94% below its 52-week high of $23.86, which the company achieved on June 6th.

Novavax (NVAX) closed the most recent trading day at $7.92, moving -1.25% from the previous trading session. Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus ...

In the closing of the recent trading day, Novavax (NVAX) stood at $8.19, denoting a +0.74% change from the preceding trading day. In the most recent trading session, Novavax (NVAX) closed at $8.45, ...